165 related articles for article (PubMed ID: 32862866)
41. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.
Kebriaei P; Saliba R; Rondon G; Chiattone A; Luthra R; Anderlini P; Andersson B; Shpall E; Popat U; Jones R; Worth L; Ravandi F; Thomas D; O'Brien S; Kantarjian H; de Lima M; Giralt S; Champlin R
Biol Blood Marrow Transplant; 2012 Apr; 18(4):584-92. PubMed ID: 21867666
[TBL] [Abstract][Full Text] [Related]
42. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.
Nishiwaki S; Imai K; Mizuta S; Kanamori H; Ohashi K; Fukuda T; Onishi Y; Takahashi S; Uchida N; Eto T; Nakamae H; Yujiri T; Mori S; Nagamura-Inoue T; Suzuki R; Atsuta Y; Tanaka J
Bone Marrow Transplant; 2016 Jan; 51(1):43-50. PubMed ID: 26389833
[TBL] [Abstract][Full Text] [Related]
43. Comparative study on allogeneic with autologous hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of TKIs: a systematic review and meta-analysis.
Wei H; Kuang P; Liu T
Ann Hematol; 2020 Nov; 99(11):2619-2628. PubMed ID: 32960314
[TBL] [Abstract][Full Text] [Related]
44. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
[TBL] [Abstract][Full Text] [Related]
45. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
[TBL] [Abstract][Full Text] [Related]
46. Value of pre-transplant consolidation chemotherapy in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation without minimal residual disease in first complete remission.
Fu W; Huang A; Lu G; Ni X; Gao L; Chen L; Chen J; Zhang W; Yang J
Leuk Lymphoma; 2021 Apr; 62(4):952-959. PubMed ID: 33174792
[TBL] [Abstract][Full Text] [Related]
47. The role of allogeneic hematopoietic stem cell transplantation in the therapy of patients with acute lymphoblastic leukemia.
Kebriaei P; Poon LM
Curr Hematol Malig Rep; 2012 Jun; 7(2):144-52. PubMed ID: 22410763
[TBL] [Abstract][Full Text] [Related]
48. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
[No Abstract] [Full Text] [Related]
49. Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy.
Lin M; Zhao X; Chang Y; Zhao X
Chin Med J (Engl); 2024 Jan; 137(2):140-151. PubMed ID: 38148315
[TBL] [Abstract][Full Text] [Related]
50. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
51. Pediatric chemotherapy versus allo-HSCT for adolescent and adult Philadelphia chromosome-negative ALL in first complete remission: a meta-analysis.
Pan Z; Wang L; Fu W; Jiang C; Zhang Z; Chen Q; Wang L; Hu X
Ann Hematol; 2023 May; 102(5):1131-1140. PubMed ID: 36947212
[TBL] [Abstract][Full Text] [Related]
52. Effects of post-remission chemotherapy before allo-HSCT for acute myeloid leukemia during first complete remission: a meta-analysis.
Zhu Y; Gao Q; Du J; Hu J; Liu X; Zhang F
Ann Hematol; 2018 Sep; 97(9):1519-1526. PubMed ID: 29946906
[TBL] [Abstract][Full Text] [Related]
53. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
Yanada M; Naoe T; Iida H; Sakamaki H; Sakura T; Kanamori H; Kodera Y; Okamoto S; Kanda Y; Sao H; Asai O; Nakai K; Maruta A; Kishi K; Furukawa T; Atsuta Y; Yamamoto K; Tanaka J; Takahashi S
Bone Marrow Transplant; 2005 Nov; 36(10):867-72. PubMed ID: 16113659
[TBL] [Abstract][Full Text] [Related]
54. Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation.
Abdelaty MM; Gawaly A; Fathy GM; Kabbash I; Taha A
J Egypt Natl Canc Inst; 2020 Jun; 32(1):28. PubMed ID: 32537680
[TBL] [Abstract][Full Text] [Related]
55. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology.
Xu L; Chen H; Chen J; Han M; Huang H; Lai Y; Liu D; Liu Q; Liu T; Jiang M; Ren H; Song Y; Sun Z; Wang J; Wu D; Zhou D; Zou P; Liu K; Huang X
J Hematol Oncol; 2018 Mar; 11(1):33. PubMed ID: 29495966
[TBL] [Abstract][Full Text] [Related]
56. Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Hamdi A; Mawad R; Bassett R; di Stasi A; Ferro R; Afrough A; Ram R; Dabaja B; Rondon G; Champlin R; Sandmaier BM; Doney K; Bar M; Kebriaei P
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1767-71. PubMed ID: 25017763
[TBL] [Abstract][Full Text] [Related]
57. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
[TBL] [Abstract][Full Text] [Related]
58. Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?
Litzow MR
Best Pract Res Clin Haematol; 2018 Dec; 31(4):357-360. PubMed ID: 30466747
[TBL] [Abstract][Full Text] [Related]
59. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia.
Ge L; Ye F; Mao X; Chen J; Sun A; Zhu X; Qiu H; Jin Z; Miao M; Fu C; Ma X; Chen F; Xue S; Ruan C; Wu D; Tang X
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1040-7. PubMed ID: 24704575
[TBL] [Abstract][Full Text] [Related]
60. [Efficacy comparison of sequential treatment with first-line administration of second-generation and first-generation tyrosine kinase inhibitors in patients with Ph
Yang F; Cai WZ; Yang XD; Chen SN; Tang XW; Sun AN; Wu DP; Qian WQ; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):110-115. PubMed ID: 29562444
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
